Gilead Sciences, Inc.: European Commission Grants Expanded Marketing Authorization for Gilead's Biktarvy for the Treatment of HIV in Pediatric Populations
- EC Authorizes a Low-Dose Tablet for HIV Treatment in Virologically Suppressed Children at Least Two Years of Age and Weighing at Least 14 kg, Helping to Address a Critical Unmet Need - - Biktarvy
Source: finanznachrichten.de